Haemonetics (HAE) vs Solventum (SOLV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Haemonetics (HAE) has outperformed Solventum (SOLV) over the past year, gaining 52.5% versus a gain of 1.9%. Solventum is the larger company by market cap ($14.36 billion vs $5.47 billion), about 2.6 times the size. On valuation, Solventum trades at a lower forward P/E (11.2x vs 19.2x for Haemonetics).
Solventum converts more of its revenue into profit, with a net margin of 18.7% versus 7.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HAE | SOLV |
|---|---|---|
| Share price | $120.16 | $84.50 |
| Market cap | $5.47B | $14.36B |
| 1-day change | -0.17% | -1.52% |
| YTD return | +49.92% | +6.64% |
| 1-year return | +52.51% | +1.93% |
| 5-year return | +131.43% | — |
| P/E ratio (TTM) | 53.17 | 94.94 |
| Forward P/E | 19.17 | 11.20 |
| EPS (TTM) | $2.26 | $0.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.33B | $8.32B |
| Revenue growth (YoY) | -1.97% | +0.86% |
| Net income (latest FY) | $97.31M | $1.56B |
| Gross margin | 59.04% | 53.47% |
| Operating margin | 11.75% | 26.20% |
| Net margin | 7.29% | 18.69% |
| 52-week high | $132.00 | $94.16 |
| 52-week low | $51.00 | $62.38 |
| Distance from 52-week high | -8.97% | -10.26% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +22.49% | +16.43% |
| Average volume | 659.70K | 1.03M |
| Shares outstanding | 45.54M | 169.96M |
| Employees | 3,009 | 20,584 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Solventum is about 2.6 times larger than Haemonetics by market value ($14.36B vs $5.47B).
- HAE has outperformed SOLV by 50.6 percentage points over the past year.
- Solventum trades at a higher earnings multiple (94.9x vs 53.2x trailing P/E).
- Solventum is more profitable, keeping 18.7 cents of every revenue dollar as net income versus 7.3 cents for Haemonetics.
About Haemonetics
HAE stock →Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments.
Health Care · Medical/Dental Instruments · 3,009 employees
About Solventum
SOLV stock →Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems.
Health Care · Medical/Dental Instruments · 20,584 employees
HAE vs SOLV FAQ
Which is bigger, Haemonetics or Solventum?
Solventum (SOLV) is larger, with a market capitalization of $14.36B compared with $5.47B for Haemonetics (HAE).
Which stock has performed better over the past year, HAE or SOLV?
HAE returned +52.51% over the past 12 months, compared with +1.93% for SOLV (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HAE or SOLV?
HAE has the lower trailing P/E at 53.2, versus 94.9 for SOLV. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Haemonetics and Solventum in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.